Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
| March 26, 2024
Read More
Vivani Medical Appoints Daniel Bradbury to its Board of Directors
| March 6, 2024
Read More
Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants
| March 1, 2024
Read More
Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic®/Wegovy® and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio
| February 28, 2024
Read More
Vivani Medical Provides Business Update and Reports Third Quarter Financial Results
| November 14, 2023
Read More
Vivani Medical to Present at BIO Investor Forum
| October 16, 2023
Read More
Vivani Medical to Present at the Boulder Peptide Symposium
| September 7, 2023
Read More
Vivani Medical Subsidiary Cortigent to Present Orion Clinical Study Results at The Eye and The Chip World Research Congress on Artificial Vision October 8-10
| September 5, 2023
Read More
Vivani Medical Reports Second Quarter Financial Results and Provides Business Update
| August 14, 2023
Read More
Vivani Medical, Inc. Subsidiary Cortigent Reports 5-Year Early Feasibility Study Update for the Orion® Visual Cortical Prosthesis System
| July 11, 2023
Read More
Blog Navigation
Contact Us
To learn more about Vivani or the upcoming First in Human trial of NPM-119 (GLP-1 implant), please fill out the form below.